Vydura Evropska unija - slovenščina - EMA (European Medicines Agency)

vydura

pfizer europe ma eeig  - rimegepant - bolezni migrene - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

Senshio Evropska unija - slovenščina - EMA (European Medicines Agency)

senshio

shionogi b.v. - ospemifen - postmenopavza - spolni hormoni in zdravila genitalni sistem, - senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (vva) in post-menopausal women.

Intrarosa Evropska unija - slovenščina - EMA (European Medicines Agency)

intrarosa

endoceutics s.a. - prasterone - postmenopavza - drugi spolni hormoni in zdravila genitalni sistem - intrarosa je indicirano za zdravljenje vulve in vaginalne atrofije v menopavzi, ki imajo zmerno do hudo simptomi.

Pyrukynd Evropska unija - slovenščina - EMA (European Medicines Agency)

pyrukynd

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Lecicarbon za odrasle 500 mg/680 mg svečke Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lecicarbon za odrasle 500 mg/680 mg svečke

athenstaedt gmbh & co kg - natrijev hidrogenkarbonat; natrijev dihidrogenfosfat - svečka - natrijev hidrogenkarbonat 500 mg / 1 svečka  natrijev dihidrogenfosfat680 mg / 1 svečka; natrijev dihidrogenfosfat 680 mg / 1 svečka - zdravila, ki razvijajo ogljikov dioksid

Lecicarbon za otroke 250 mg/340 mg svečke Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lecicarbon za otroke 250 mg/340 mg svečke

athenstaedt gmbh & co kg - natrijev hidrogenkarbonat, natrijev dihidrogenfosfat - svečka - natrijev hidrogenkarbonat 250 mg / 1 svečka; natrijev dihidrogenfosfat 340 mg / 1 svečka - zdravila, ki razvijajo ogljikov dioksid

Celvapan Evropska unija - slovenščina - EMA (European Medicines Agency)

celvapan

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - cepiva - preprečevanje gripe, ki jo povzroča virus a (h1n1) v 2009. celvapan je treba uporabljati v skladu z uradnimi smernice.

Stelfonta Evropska unija - slovenščina - EMA (European Medicines Agency)

stelfonta

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - psi - za zdravljenje ne-resectable, non-metastatskim (ki uprizoritev) podkožnega jambor celice tumorji, ki se nahajajo na ali v distalni komolca ali hock, in non-resectable, ne metastatskim kožne jambor celice tumorjev pri psih.

Ayvakyt Evropska unija - slovenščina - EMA (European Medicines Agency)

ayvakyt

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinalni stromalni tumorji - druga zdravila z delovanjem na novotvorbe agenti, protein kinaza inhibitorji - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Libmeldy Evropska unija - slovenščina - EMA (European Medicines Agency)

libmeldy

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - druga zdravila na živčnem sistemu - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.